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A
 
BSTRACT
 
Background
 
Voriconazole is a broad-spectrum tri-
azole that is active against aspergillus species. We
conducted a randomized trial to compare voriconazole
with amphotericin B for primary therapy of invasive
aspergillosis.
 
Methods
 
In this randomized, unblinded trial, pa-
tients received either intravenous voriconazole (two
doses of 6 mg per kilogram of body weight on day 1,
then 4 mg per kilogram twice daily for at least seven
days) followed by 200 mg orally twice daily or intra-
venous amphotericin B deoxycholate (1 to 1.5 mg per
kilogram per day). Other licensed antifungal treat-
ments were allowed if the initial therapy failed or if
the patient had an intolerance to the first drug used.
A complete or partial response was considered to be
a successful outcome.
 
Results
 
A total of 144 patients in the voriconazole
group and 133 patients in the amphotericin B group
with definite or probable aspergillosis received at least
one dose of treatment. In most of the patients, the un-
derlying condition was allogeneic hematopoietic-cell
transplantation, acute leukemia, or other hematologic
diseases. At week 12, there were successful outcomes
in 52.8 percent of the patients in the voriconazole
group (complete responses in 20.8 percent and partial
responses in 31.9 percent) and 31.6 percent of those
in the amphotericin B group (complete responses in
16.5 percent and partial responses in 15.0 percent; ab-
solute difference, 21.2 percentage points; 95 percent
confidence interval, 10.4 to 32.9). The survival rate at
12 weeks was 70.8 percent in the voriconazole group
and 57.9 percent in the amphotericin B group (hazard
ratio, 0.59; 95 percent confidence interval, 0.40 to 0.88).
Voriconazole-treated patients had significantly fewer
severe drug-related adverse events, but transient
visual disturbances were common with voriconazole
(occurring in 44.8 percent of patients).
 
Conclusions
 
In patients with invasive aspergillosis,
initial therapy with voriconazole led to better respons-
es and improved survival and resulted in fewer severe
side effects than the standard approach of initial
therapy with amphotericin B. (N Engl J Med 2002;347:
408-15.)
 
Copyright © 2002 Massachusetts Medical Society.
 
From the Hôpital de Hautepierre, Strasbourg, France (R.H.); the Univer-
sity of Manchester, Manchester, United Kingdom (D.W.D.); the University
of Texas Health Science Center, San Antonio (T.F.P.); the National Institute
of Allergy and Infectious Diseases, Bethesda, Md. (J.E.B.); Massachusetts
General Hospital, Boston (R.E.G.); Charité, Campus Virchow-Klinikum,
Berlin, Germany (J.-W.O.); Medizinische Universitätsklinik, Freiburg, Ger-
many (W.V.K.); Fred Hutchinson Cancer Research Center, Seattle (K.A.M.);
Hôpital Saint-Louis, Paris (P.R.); Institut Pasteur, Paris (O.L.); the European
Organisation for Research and Treatment of Cancer, Brussels, Belgium (R.S.);
Brigham and Women’s Hospital, Boston (R.H.R.); the University of Florida
College of Medicine, Gainesville (J.R.W.); the University of California at
San Diego, San Diego (P.S.); Hôpital du Bocage, Dijon, France (C.D., D.C.);
University Hospital Benjamin Franklin, Berlin, Germany (E.T.); Wayne State
University School of Medicine, Detroit (P.H.C.); Pfizer Global Research
and Development, New York (M.R.H., H.T.S.) and Sandwich, United King-
dom (P.F.T.); and University Medical Center, Nijmegen, the Netherlands
(B.P.). Address reprint requests to Dr. Herbrecht at the Département d’Hé-
matologie et d’Oncologie, Hôpital de Hautepierre, Ave. Molière, 67098
Strasbourg CEDEX, France, or at raoul.herbrecht@chru-strasbourg.fr.
*Other members of the study are listed in the Appendix.
 
NVASIVE aspergillosis is a major infectious com-
plication in patients with prolonged neutropenia
and in transplant recipients. Its incidence ranges
from 5 percent to more than 20 percent in high-
risk groups.
 
1
 
 For decades, amphotericin B deoxycho-
late has been the standard therapy for invasive as-
pergillosis, although responses are suboptimal (less
than 40 percent) in severely immunosuppressed pa-
tients.
 
1-3
 
 Amphotericin B is associated with multiple
side effects, which may be ameliorated with the use
of lipid formulations.
 
4-6
 
Voriconazole is a new broad-spectrum triazole that
is active in vitro against various yeasts and molds, in-
cluding aspergillus species.
 
7
 
 A noncomparative study
demonstrated a response rate of 48 percent among pa-
tients with acute invasive aspergillosis.
 
8
 
 We undertook
an open, randomized trial comparing the efficacy, safe-
ty, and tolerability of voriconazole with those of am-
photericin B for the primary therapy of acute invasive
aspergillosis in immunocompromised patients; both
types of therapy were followed by other licensed anti-
fungal therapy when toxic effects or insufficient re-
sponse dictated.
 
METHODS
 
Conduct of the Study
 
Two identical protocols (protocol 150-307 in Europe, Israel,
and Australia and protocol 150-602 in the United States, Canada,
I
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Mexico, Brazil, and India) were designed under the aegis of an in-
ternational steering committee that included the Invasive Fungal
Infections Group of the European Organisation for Research and
Treatment of Cancer (EORTC). The protocols were approved by
the appropriate institutional review boards, and written informed
consent was obtained from all patients or their parents or guardians.
The studies were assessed by an independent data review commit-
tee consisting of eight clinicians and four radiologists and were
monitored by two data and safety monitoring boards. Statistical
analysis was conducted by the EORTC Data Center. The study’s
sponsor, Pfizer, allowed the investigators independence in study
design and analysis. The data were held at the EORTC Data Cen-
ter in Brussels, Belgium, and at Pfizer.
 
Study Patients
 
Eligible patients were those with definite or probable invasive
aspergillosis who were 12 years of age or older and were immuno-
compromised because of one of the following: allogeneic hema-
topoietic-cell transplantation; autologous hematopoietic-cell trans-
plantation, hematologic cancer, aplastic anemia, or myelodysplastic
syndrome; or other immunocompromising conditions, including
the acquired immunodeficiency syndrome (AIDS), receipt of cor-
ticosteroid therapy, and solid-organ transplantation.
Definite invasive aspergillosis was defined as a clinically compat-
ible illness plus one or more of the following: isolation of aspergil-
lus species from a normally sterile site; hyphae consistent with the
presence of aspergillus in a biopsy specimen or aspirate, plus culture
of aspergillus from the same organ; radiologic evidence of pulmo-
nary lesions that were not attributable to other factors and a culture
of bronchoalveolar-lavage fluid that was positive for aspergillus in
a patient who had undergone allogeneic hematopoietic-cell trans-
plantation or who had a neutropenic hematologic condition; or tra-
cheobronchial lesions confirmed by bronchoscopy, with a positive
culture for aspergillus. Neutropenia was defined by a neutrophil
count of less than 500 per cubic millimeter at some point during
the previous two weeks.
Probable invasive aspergillosis was defined as a clinically com-
patible illness plus one or more of the following: hyphae consistent
with the presence of aspergillus in a biopsy specimen or aspirate
but without culture; the presence of a halo or an air-crescent sign
on a computed tomographic (CT) scan of the lung
 
9
 
 in a patient
who had undergone allogeneic hematopoietic-cell transplantation
or who had a neutropenic hematologic condition; radiologic ev-
idence of new pulmonary lesions that were not attributable to
other factors in a patient who had undergone allogeneic hemato-
poietic-cell transplantation or who had a neutropenic hematologic
condition with either hyphae consistent with the presence of as-
pergillus in bronchoalveolar-lavage fluid or sputum or a sputum
culture that was positive for aspergillus; clinical evidence of sinusitis,
opacification of a sinus on CT or magnetic resonance imaging, and
positive histopathological examination or culture of aspergillus from
a lesion in the nose or paranasal sinus in a patient who had under-
gone allogeneic hematopoietic-cell transplantation or who had a
neutropenic hematologic condition; radiologic evidence of new pul-
monary lesions that were not attributable to other factors and bron-
choalveolar-lavage fluid that was positive for aspergillus on a smear
or culture in a patient with another immunocompromising condi-
tion (other than lung transplantation); or tracheobronchial lesions
confirmed by bronchoscopy and a positive finding on histopatho-
logical or microscopic examination of a biopsy specimen or bron-
choalveolar lavage fluid.
Patients were ineligible if they had chronic aspergillosis, aspergillo-
ma, or allergic bronchopulmonary aspergillosis or had received sys-
temic therapy for more than 96 hours with more than 0.5 mg of
amphotericin B per kilogram of body weight per day (including
lipid derivatives) or more than 200 mg of itraconazole per day dur-
ing the preceding 14 days. Patients were also ineligible if they had
received or were receiving interacting drugs (e.g., rifampin), were
hypersensitive to azoles or amphotericin B, or had an aminotrans-
ferase, bilirubin, or alkaline phosphatase level higher than five times
the upper limit of normal or a serum creatinine level higher than
2.5 mg per deciliter (221 µmol per liter). Patients who were receiv-
ing artificial ventilation, who had a life expectancy of less than 72
hours, or who were pregnant or lactating were also ineligible.
 
Study Design
 
With the use of central randomization according to the minimi-
zation technique,
 
10
 
 patients were assigned to treatment groups, with
stratification according to the center, the site of infection (pulmo-
nary or other), the underlying condition (allogeneic hematopoi-
etic-cell transplantation, hematologic condition, or other immuno-
compromising condition), and the base-line neutropenic status
(neutropenic or nonneutropenic). Patients received primary therapy
with either voriconazole (6 mg per kilogram intravenously twice a
day on day 1, followed by 4 mg per kilogram intravenously twice
daily for at least seven days, after which time patients could switch
to oral voriconazole, 200 mg twice daily) or intravenous amphoter-
icin B deoxycholate (1.0 to 1.5 mg per kilogram once daily). Pa-
tients with an intolerance or no response to the initial therapy
could be switched to other licensed antifungal therapy and con-
tinue to be included in the analyses. The planned duration of ther-
apy was 12 weeks. Administration of study drugs was discontinued
in cases of severe adverse events, an increase in the serum creatinine
level to double the base-line value or more than 3.0 mg per deciliter
(265 µmol per liter) if the base-line value was higher than 1.5 mg
per deciliter (133 µmol per liter), or an increase in aminotransfer-
ase levels to more than 5 times the upper limit of normal or 10
times the upper limit of normal if the base-line value was more
than 2 times the upper limit of normal.
The data-review committee, which was blinded to the study-drug
assignment and to adverse events and laboratory abnormalities
whose presence would suggest the use of a particular study drug,
assessed the certainty of the diagnosis at study entry and the re-
sponse to treatment on the basis of predefined criteria. The com-
mittee assessed the global response at week 12 and at the end of the
initial period of randomized therapy.
Digitized radiologic images were reviewed by the radiologists
on the data-review committee. Lesions were evaluated visually for
changes with the use of computerized planimetry for assistance in
estimating the percentage change. Complete responses were de-
fined by the resolution of all clinical signs and symptoms and more
than 90 percent of the lesions due to invasive aspergillosis that
were visible on radiology. Partial responses were defined by clinical
improvement and greater than 50 percent improvement in find-
ings on radiology. Stable responses were defined by the absence
of change from base line or an improvement of less than 50 per-
cent. Failure of therapy was defined by worsening disease. Com-
plete and partial responses were classified as successful outcomes.
Stable and indeterminate responses and failures of therapy were
regarded as unsuccessful outcomes.
 
Statistical Analysis
 
Before the two studies began, we planned to combine the results
of both in a predefined analysis. The intention-to-treat population
consisted of all patients who underwent randomization. The mod-
ified intention-to-treat population consisted of those who received
at least one dose of the medication they were initially assigned to
receive and who had a base-line diagnosis of definite or probable
invasive aspergillosis as confirmed by the data-review committee.
The population included in the safety analysis consisted of all pa-
tients who received their initial study medication.
The primary objective of the studies was to demonstrate the
noninferiority of voriconazole as compared with amphotericin B
at week 12 in the modified intention-to-treat population. We es-
timated that the rate of successful outcomes with amphotericin B
at week 12 would be 50 percent. Voriconazole would be consid-
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ered not to be inferior to amphotericin B if the lower limit of the
two-sided 95 percent confidence interval for the difference in vor-
iconazole response rate minus the difference in amphotericin B re-
sponse rate was above ¡20 percentage points.
One secondary objective was the demonstration of the superi-
ority of the response to voriconazole at the end of the initial ther-
apy in the modified intention-to-treat population — as indicated
by a two-sided 95 percent confidence interval entirely above zero
for the difference between the proportion with a complete or par-
tial response in the voriconazole group and the proportion in the
amphotericin B group. Other secondary objectives were to compare
the safety of the two drugs and the duration of survival in the
two groups up to week 12.
A sample size of 276 was required to assess the primary end
point with at least 90 percent power. We compared the responses
by calculating the estimated difference between the response rates,
with stratification according to study protocol (150-307 or 150-
602), and the corresponding approximate two-sided 95 percent
confidence interval. The hazard ratio for death was estimated by
the Cox proportional-hazards model, with stratification according
to study. The numbers of adverse events were compared by Fisher’s
exact test. The mean numbers of adverse events were compared
by the Wilcoxon rank-sum test. All tests were two-sided.
 
RESULTS
 
Enrollment and Base-Line Characteristics of the Patients
 
Between July 1997 and October 2000, a total of
391 patients recruited by 95 centers in 19 countries
underwent randomization in the studies: 252 pa-
tients were recruited in the 150-307 protocol and 139
in the 150-602 protocol.
A total of 197 patients were assigned to the voricon-
azole group, and 194 patients were assigned to the
amphotericin B group; these patients comprised the
intention-to-treat population. Twelve patients (three
in the voriconazole group and nine in the ampho-
tericin B group) did not receive any treatment and
were excluded from the safety analyses. A total of 102
patients (50 in the voriconazole group and 52 in the
amphotericin B group) were excluded from the mod-
ified intention-to-treat population because they did
not have a confirmed diagnosis of invasive aspergillo-
sis at base line. The most common reason for the
lack of confirmation was the inability of the data-
review committee to confirm the presence of a halo
or air-crescent sign at base line in patients with no
supporting mycologic or pathological evidence (35
in the voriconazole group and 25 in the amphotericin
B group). Other reasons included inadequate myco-
logic evidence (in 10 patients in the voriconazole
group and 15 in the amphotericin B group), no ra-
diologic evidence of pulmonary or sinus infection
(in 1 patient in the voriconazole group and 4 in the
amphotericin B group), and absence of documenta-
tion of neutropenia or immunocompromised condi-
tion before base line (in 4 patients in the voricona-
zole group and 8 in the amphotericin B group).
The demographic characteristics and underlying
conditions of the patients in the modified intention-
to-treat population are summarized in Table 1. The
two groups were well matched, and there was no sig-
nificant difference in these characteristics between the
intention-to-treat population and the modified in-
tention-to-treat population. Patients enrolled accord-
ing to the 150-602 protocol were more likely than
those enrolled according to the 150-307 protocol to
have undergone allogeneic hematopoietic-cell trans-
plantation (41 of 107 [38.3 percent] vs. 26 of 170
[15.3 percent], P<0.001), to have graft-versus-host
disease (31 of 107 [29.0 percent] vs. 16 of 170 [9.4
percent], P<0.001), and to have received a definite
diagnosis of invasive aspergillosis (51 of 107 [47.7
percent] vs. 57 of 170 [33.5 percent], P=0.02), and
they were less likely to have neutropenia (28 of 107
[26.2 percent] vs. 95 of 170 [55.9 percent],
P<0.001).
 
Base-Line Characteristics of the Infection
 
Characteristics of the patients in terms of the site
of the infection, the level of certainty of the diagnosis,
and the evidence supporting the diagnosis are sum-
marized in Table 2. The only significant difference
between groups was that the voriconazole group had
a higher proportion of definite cases of invasive as-
pergillosis (P=0.01). In the 110 infections in which
the species was identified at base line, the species was
 
*Neutropenia was defined by a neutrophil count of less than 500 per
cubic millimeter at base line or during the previous two weeks.
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(N=144)
A
 
MPHOTERICIN
 
 B
G
 
ROUP
 
(N=133)
 
Age — yr
Mean 48.5 50.5
Range 13–79 12–75
Sex — no. (%)
Male 98 (68.1) 89 (66.9)
Female 46 (31.9) 44 (33.1)
Weight — kg
Mean 70.4 71.0
Range 39–123 28–118
Underlying condition — no. (%)
Allogeneic hematopoietic-cell 
transplantation
37 (25.7) 30 (22.6)
Autologous hematopoietic-cell 
transplantation
6 (4.2) 6 (4.5)
Acute leukemia 58 (40.3) 60 (45.1)
Other hematologic cancer 17 (11.8) 18 (13.5)
Solid-organ transplantation 9 (6.2) 5 (3.8)
AIDS 6 (4.2) 7 (5.3)
Corticosteroid treatment 9 (6.2) 7 (5.3)
Other 2 (1.4) 0
Neutropenia — no. (%)*
Yes 65 (45.1) 60 (45.1)
No 79 (54.9) 73 (54.9)
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Aspergillus fumigatus 
 
(in 85 patients), 
 
A. niger
 
 (in
9 patients), 
 
A. flavus
 
 (in 7 patients), A. terreus (in 6 pa-
tients), A. glaucus (in 1 patient), A. nidulans (in 1 pa-
tient), and A. sydowii (in 1 patient).
Course of Therapy in the Modified Intention-to-Treat 
Population
The median duration of voriconazole treatment was
77 days (range, 2 to 84), of which intravenous therapy
accounted for a median of 10 days (range, 2 to 78).
The mean daily doses were 7.87 mg per kilogram
(range, 4.48 to 10.87) during the intravenous phase
and 416 mg (range, 200 to 750) during the oral
phase. Other licensed antifungal therapy was given to
52 patients in the voriconazole group. The first other
licensed antifungal therapy was amphotericin B deoxy-
cholate in 20 patients, a lipid formulation of ampho-
tericin B in 14, itraconazole in 17, and a combina-
tion in 1.
The median duration of amphotericin B treatment
was 10 days (range, 1 to 84), and the mean daily dose
was 0.97 mg per kilogram (range, 0.27 to 1.50). Dur-
ing the first 14 days of therapy, administration of am-
photericin B was suspended for more than 1 day in 13
patients. Other licensed antifungal therapy was given
to 107 patients in the amphotericin B group. The
first other licensed antifungal therapy was a lipid for-
mulation of amphotericin B in 47 patients, itracona-
zole in 38, and another antifungal drug or a combi-
nation of drugs in 22.
Response
The outcome at week 12 in the modified intention-
to-treat population was significantly better in patients
receiving voriconazole, with a successful outcome in
76 of 144 patients (52.8 percent), as compared with
42 of 133 patients (31.6 percent) in the amphotericin
B group (Table 3). The absolute difference was 21.2
percent, with a 95 percent confidence interval for the
difference between groups stratified according to
the study protocol of 10.4 to 32.9 percentage points.
Since the lower 95 percent confidence limit for the
difference between voriconazole and amphotericin B
was above zero, voriconazole was considered not only
not to be inferior to amphotericin B, but also to be
superior to it.
Retrospective stratification according to the level of
certainty of the diagnosis, the site of infection, the un-
derlying condition, or the neutropenic status did not
change the overall conclusions. Responses in patients
receiving voriconazole appeared to be superior at week
12 in all the various subgroups (Fig. 1). Of 95 patients
included with a diagnosis of probable aspergillosis that
was based on the presence of a halo sign without mi-
crobiologic confirmation, 31 in the voriconazole
group (67.4 percent) had a successful outcome, as
compared with 21 (42.9 percent) in the amphoteri-
cin B group. The difference (24.5 percentage points in
favor of voriconazole) was almost identical to that
among all patients with probable aspergillosis — 22.7
percentage points in favor of voriconazole.
In the intention-to-treat population, a successful
outcome at week 12 was observed in 49.7 percent of
the patients in the voriconazole group and 27.8 per-
*Category includes those with other organ involvement.
†Category excludes those with cerebral involvement.
‡There were significantly more definite cases in the voriconazole group
(P=0.01).
§Some patients had more than one type of biologic evidence.
TABLE 2. SITE OF THE INFECTION, DEGREE OF CERTAINTY, 
AND EVIDENCE SUPPORTING BASE-LINE DIAGNOSIS 
IN THE MODIFIED INTENTION-TO-TREAT POPULATION.
VARIABLE
VORICONAZOLE
GROUP
(N=144)
AMPHOTERICIN B
GROUP
(N=133)
no. (%)
Site of the infection
Lung only 123 (85.4) 117 (88.0)
Sinus 8 (5.6) 7 (5.3)
Cerebral* 5 (3.5) 5 (3.8)
Disseminated† 4 (2.8) 1 (0.8)
Other 4 (2.8) 3 (2.3)
Level of certainty of the diagnosis
of aspergillosis
Definite‡ 67 (46.5) 41 (30.8)
Probable 77 (53.5) 92 (69.2)
Initial evidence of aspergillosis§
Positive finding on microscopy 56 (38.9) 46 (34.6)
Positive culture 84 (58.3) 65 (48.9)
Positive histologic examination 35 (24.3) 22 (16.5)
Halo or air-crescent sign only 46 (31.9) 49 (36.8)
*The 95 percent confidence interval around the difference
in successful outcomes (stratified according to study) was
10.4 to 32.9 percent.
TABLE 3. RESPONSE RATE AT WEEK 12 IN THE 
MODIFIED INTENTION-TO-TREAT POPULATION.
RESPONSE
VORICONAZOLE
GROUP
(N=144)
AMPHOTERICIN B
GROUP
(N=133)
no. (%)
Successful outcome* 76 (52.8) 42 (31.6)
Complete response 30 (20.8) 22 (16.5)
Partial response 46 (31.9) 20 (15.0)
Unsuccessful outcome 68 (47.2) 91 (68.4)
Stable disease 8 (5.6) 8 (6.0)
Failure of therapy 55 (38.2) 78 (58.6)
Indeterminate 5 (3.5) 5 (3.8)
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cent of those in the amphotericin B group (absolute
difference, 21.9 percent; 95 percent confidence in-
terval, 12.4 to 31.2).
At the end of the initial period of randomized
therapy, 53.5 percent of the patients in the modified
intention-to-treat population who were receiving vor-
iconazole had a satisfactory response, as compared
with 21.8 percent of the patients treated with ampho-
tericin B (absolute difference, 31.7 percent; 95 per-
cent confidence interval, 21.1 to 42.6). There were
similar results in the intention-to-treat population.
Survival
At week 12, the survival rate was 70.8 percent in
the patients in the modified intention-to-treat pop-
ulation who were treated with voriconazole, as com-
pared with 57.9 percent in the amphotericin B group
(hazard ratio, 0.59; 95 percent confidence interval,
Figure 1. Response Rates in the Modified Intention-to-Treat Population, According to the Study Protocol, Site of Infection, Underlying
Condition, Neutropenic Status, and Degree of Certainty of the Diagnosis, and in the Intention-to-Treat Population.
Results are expressed as the differences (with 95 percent confidence intervals) between the voriconazole group and the amphoter-
icin B group in the rate of successful outcomes.
¡20 6040200
Difference in Proportions 
(percentage points)
Successful Outcome (%)
Amphotericin
B group
Voriconazole
group
 Protocol 150-602 46.6
Pulmonary infection only 54.5
Overall intention-to-treat
population 49.7
Extrapulmonary infection 42.9
Allogeneic hematopoietic-cell
transplantation 32.4
Neutropenic hematologic
condition 63.0
Other immunocompromising
condition 50.0
Neutropenia 50.8
No neutropenia 54.3
Definite aspergillosis 44.8
Probable aspergillosis 59.7
Modified intention-to-
treat population 52.8
 Protocol 150-307 57.0
22.5
34.2
27.8
12.5
13.3
38.1
31.6
31.7
31.5
19.5
37.0
31.6
36.9
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0.40 to 0.88) (Fig. 2). Similar results were observed
in the intention-to-treat population.
Safety
Significantly fewer adverse events that were regard-
ed by the investigators as potentially related to treat-
ment were observed during voriconazole therapy (343
events) than during amphotericin B therapy (421
events, P=0.02), even though the median duration
of therapy was much longer in the voriconazole
group. Visual disturbances were more common in
patients receiving voriconazole, occurring in 87 pa-
tients (44.8 percent), as compared with 8 patients in
the amphotericin B group (4.3 percent, P<0.001).
The most frequent descriptions of such disturbances
were blurred vision, altered visual perception, altered
color perception, and photophobia. All visual events
were transient and resolved without intervention.
Thirteen patients receiving voriconazole had halluci-
nations or confusion that was considered to be pos-
sibly related to the study drug, as compared with five
patients in the amphotericin B group (P=0.09).
There was no evidence of a relation between the ep-
isodes of hallucination or confusion and visual dis-
turbance (P=0.20). Chills, fever, or both that were
potentially related to the study drugs were recorded
in six patients receiving voriconazole (3.1 percent), as
compared with 46 patients receiving amphotericin B
therapy (24.9 percent, P<0.001). Skin reactions (rash,
pruritus, or photosensitivity) were observed in 16
patients in the voriconazole group (8.2 percent) and
in 6 in the amphotericin B group (3.2 percent,
P=0.05).
Fewer severe adverse events that were potentially
related to the study drug occurred in the voricona-
zole group (26 patients [13.4 percent]) than in the
amphotericin B group (45 patients [24.3 percent],
P=0.008) (Table 4). The most frequent events were
renal impairment (in 19 patients) in the amphoteri-
cin B group and liver-function abnormalities (in 7 pa-
tients) in the voriconazole group.
DISCUSSION
We conducted a large randomized, comparative
study of the efficacy of two different drugs in the pri-
mary treatment of invasive aspergillosis. Previous stud-
ies either compared two doses of liposomal ampho-
tericin B or used historical controls.11,12 Definitions
used in this study were determined by a consensus of
international investigators and proved sufficiently clear
for a blinded data-review committee to use for con-
firmation. The largest discrepancy between the diag-
noses of investigators and the determinations of the
data-review committee resulted not from misinter-
pretation of the diagnostic criteria but from the lack
of confirmation by the radiologists on the data-
Figure 2. Survival Curves for the Modified Intention-to-Treat Population According to Treat-
ment Group.
The P value was calculated by the log-rank test.
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review committee of the presence of a halo or air-
crescent sign on a CT scan of the lungs in 60 cases.
This open study compared two management strat-
egies for invasive aspergillosis, one of which reflects
the common clinical practice of treating patients with
conventional amphotericin B and then changing drugs
as dictated by the occurrence of toxic effects or a lack
of response. Patients treated according to this strat-
egy fared worse in terms of efficacy, toxic effects, and
survival than those who instead began treatment with
voriconazole.
The superiority of voriconazole in our study was
not the result of excessive interruptions of therapy or
insufficient doses in patients receiving amphotericin B.
The duration of treatment is unlikely to be the only
factor contributing to the better overall results with
voriconazole. Acute invasive aspergillosis is a rapidly
progressive infection, and its outcome is determined
early in the course of therapy. In the highly immu-
nosuppressed patients enrolled in this study, initial
therapy with voriconazole proved superior to initial
therapy with conventional amphotericin B. The pres-
ence of more definite cases of aspergillosis among
patients in the voriconazole group did not bias the
results, because the superiority of voriconazole was
similar in both definite and probable cases. The dif-
ference in the rate of successful outcomes between
the 150-602 and 150-307 studies can be explained
by the fact that the group involved in the former
study included more patients who either had a diag-
nosis of definite aspergillosis or had undergone allo-
geneic hematopoietic-cell transplantation.
The efficacy of voriconazole in invasive aspergillo-
sis shown in this trial is consistent with the results of
the recently published comparison of voriconazole
with liposomal amphotericin B for empirical antifun-
gal therapy in persistently febrile patients with neu-
tropenia.13 In that study, a secondary analysis found
that among the 415 patients who received voricon-
azole, only 8 (1.9 percent) had breakthrough mycosis
(4 of the cases involving aspergillus species), as com-
pared with 21 (5.0 percent, 13 of the cases involving
aspergillus species) among the 422 patients who re-
ceived liposomal amphotericin B.
Voriconazole was better tolerated than amphoter-
icin B, with fewer drug-related adverse events, severe
adverse events, and discontinuations of therapy due to
adverse events. Infusion-related adverse events and
nephrotoxic effects are common in patients receiving
amphotericin B but were not observed in patients re-
ceiving voriconazole.
Although visual adverse events were frequent in
*The 12 patients (3 in the voriconazole group and 9 in the amphotericin B group) who did not
receive any treatment were excluded from the analysis.
†P values are given for events for which there was sufficient frequency to permit a comparison be-
tween groups.
TABLE 4. SEVERE ADVERSE EVENTS POTENTIALLY 
RELATED TO INITIAL RANDOMIZED THERAPY.*
TYPE OF EVENT
VORICONAZOLE
GROUP
(N=194)
AMPHOTERICIN B
GROUP
(N=185)
P
VALUE†
no. of patients
Renal impairment 2 19 <0.00
1
Hypokalemia 0 6 0.01
Other metabolic event (hypoglycemia, hypoalbuminemia, 
worsening of adrenal insufficiency, or metabolic acidosis)
4 2 0.69
Hepatic abnormalities 7 4 0.54
Systemic event (fever, chills, anaphylaxis, asthenia, 
or myalgia)
1 7 0.03
Dyspnea 0 4 0.06
Digestive tract event (nausea, vomiting, dysgeusia, 
abdominal pain, or pancreatitis)
4 1 0.37
Hypotension 1 0
Hematologic event (thrombocytopenia, eosinophilia, or 
exacerbation of paroxysmal nocturnal hemoglobinuria)
2 1
Rash 1 0
Neurologic event (progressive encephalopathy, hallucina-
tions, or Guillain–Barré syndrome)
2 1
Visual events 2 0
The New England Journal of Medicine 
Downloaded from nejm.org at Radboud University Nijmegen on April 10, 2018. For personal use only. No other uses without permission. 
 Copyright © 2002 Massachusetts Medical Society. All rights reserved. 
VORICONAZOLE IN INVASIVE ASPERGILLOSIS
N Engl J Med, Vol. 347, No. 6 · August 8, 2002 · www.nejm.org · 415
patients receiving voriconazole, they were transient
and generally mild or moderate, and they seldom re-
sulted in discontinuation of treatment. Hallucination
and episodes of confusion were more frequent with
voriconazole than with amphotericin B, although it
is unclear whether the antifungal drug was the cause
of such episodes in these critically ill patients. This
study shows the superiority of voriconazole over am-
photericin B as initial therapy for invasive aspergillosis,
in terms of response rate, survival rate, and safety.
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